You are here

Real-time Modulated Imaging for Assessment of Tissue Viability Prior to Skin Grafts

Award Information
Agency: Department of Defense
Branch: Defense Health Agency
Contract: W81XWH-17-C-0171
Agency Tracking Number: H17A-006-0042
Amount: $146,600.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: DHA17A-006
Solicitation Number: 2017.0
Timeline
Solicitation Year: 2017
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-08-01
Award End Date (Contract End Date): 2018-02-28
Small Business Information
17151 Gillette Ave
Irvine, CA 92614
United States
DUNS: 603130928
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Amaan Mazhar
 VP Research and Development
 (949) 596-7512
 amaan.mazhar@modulatedimaging.com
Business Contact
 Frederick Ayers
Phone: (949) 596-7493
Email: fred.ayers@modulatedimaging.com
Research Institution
 Regents of the University of Califo
 David Cuccia
 
Applied Innovation, 5141 Calif
Irvine, CA 92612
United States

 (949) 596-7492
 Nonprofit college or university
Abstract

There is a lack of quantitative tools to accurately map tissue viability in a rapid and quantitative manner so a surgeon can properly excise tissue prior to grafting. Spatial Frequency Domain Imaging (SFDI) is an optical method that has been shown to be a reliable method for physiology assessment - particularly for burn depth. SFDI measures of tissue structure (scattering) and function (hemoglobin, oxygen saturation, edema) give unique insight into tissue health due to widefield diagnostic capabilities over large curved surfaces and different skin tones. Currently, our company has a FDA cleared cart-based system with indications for measuring oxygen levels in patients who have circulatory compromise. In Phase 1 of this effort, we will partner with University of California, Irvine and build a benchtop SFDI system that utilizes recent advances to test a compact, portable, lightweight version of the system suited for tissue viability measurement as burn surgeons excise tissue. We will directly compare the performance of our device to our FDA-cleared system in a series of validated phantom studies. Upon conclusion of Phase 1, we will be in position to build a clinic-ready system in Phase II for preclinical and clinical burn tissue viability studies.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government